- Home
- NX vs ORIC Comparison
NX vs ORIC Comparison
Compare NX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NX | ORIC |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.1M | 837.3M |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NX | ORIC |
|---|---|---|
| Price | $16.84 | $7.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $28.00 | $19.73 |
| AVG Volume (30 Days) | 251.4K | ★ 1.3M |
| Earning Date | 06-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,837,641,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.81 | N/A |
| 52 Week Low | $11.04 | $5.00 |
| 52 Week High | $22.90 | $14.93 |
Technical Indicators
Market Signals| Indicator | NX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 33.43 | 29.64 |
| Support Level | $16.61 | $7.90 |
| Resistance Level | $20.24 | $13.89 |
| Average True Range (ATR) | 0.82 | 0.47 |
| MACD | -0.38 | -0.12 |
| Stochastic Oscillator | 18.75 | 6.71 |
Price Performance
Historical ComparisonAbout NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.